OBJECTIVES: Golimumab intravenous (IV) is an approved biologic therapy for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). Drug reimbursement decisions are generally based on therapeutic value, cost-effectiveness, and burden of disease. The potential financial or budget impact of granting access to a product is an important factor when making reimbursement decisions as part of a comprehensive economic evaluation of a new health technology.To evaluate the potential financial impact of golimumab in the treatment of moderately to severely active rheumatoid arthritis (RA) in Chile. METHODS: A budget impact model, employing a third-party payer perspective, with a two-year time horizon was developed. Population demographics were used to calculate the number of AR eligible patients to receive treatment with biologic therapies. Current and forecasted hypothetical market share sizes were applied for selected biologic products for this indication. Two scenarios were stated: without golimumab IV – with golimumab IV. Annual dose frequency was based on labeled dosing for each indication as stated in product´s prescribing information. Pricing inputs for all biologics were based on public listed prices of CESFAR as of 01/01/2015. IV administration costs were obtained from interviews with private payers. RESULTS: In a population of 2098 eligible patients for treatment with biological products: the total annual cost of treatment and total cost per patient per year were similar for both scenarios across the two years’ time horizon with a tendency which favored the adoption of golimumab IV  (Year 1: -1,20%), which increased in the second year (Year 2: -2.23%) for a total cost of treatment and total cost per patient over 2 years of -1,71%. CONCLUSIONS: Addition of golimumab IV in local formularies in Chile is budget favorable and does not impact negatively the annual health care budget of a payer while adding another therapeutic option for patients.